MDCX vs. GSK

Last updated Aug 1, 2026

MDCX (Medicus Pharma Ltd) and GSK (GSK plc) are both stocks. Both are in the Healthcare sector — MDCX in Biotechnology, GSK in Drug Manufacturers - General. Over the past year, MDCX returned -89.29% vs 42.78% for GSK. Their 0.05 correlation means their historical movements had little consistent relationship.

Performance

MDCX vs. GSK - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Medicus Pharma Ltd (MDCX) and GSK plc (GSK). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, MDCX achieves a -82.01% return, which is significantly lower than GSK's 7.22% return.

MDCX

• 1D: 4.80%
• 1M: -33.89%
• 6M: -76.87%
• YTD: -82.01%
• 1Y: -89.29%
• 3Y*: —
• 5Y*: —
• 10Y*: —
• ALL TIME*: -75.77%

GSK

• 1D: -0.73%
• 1M: -3.67%
• 6M: 1.90%
• YTD: 7.22%
• 1Y: 42.78%
• 3Y*: 18.53%
• 5Y*: 4.82%
• 10Y*: 3.76%
• ALL TIME*: 8.48%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Liquidity Comparison

Position	Avg. Volume Value (2W)	Avg. Volume Value (1M)	Avg. Volume Value (3M)
GSK GSK plc	$276.89M	$237.83M	$206.74M
MDCX Medicus Pharma Ltd	$505.47K	$499.43K	$773.71K

MDCX vs. GSK - Yearly Performance Comparison

	2026 (YTD)	2025	2024
MDCX Medicus Pharma Ltd	-82.01%	-37.04%	-21.61%
GSK GSK plc	7.22%	51.23%	-2.57%

Correlation

The correlation between MDCX and GSK is 0.05, meaning there was essentially no consistent relationship between their historical price movements. Each responded to its own set of market drivers.

	Correlation
Correlation (1Y) Focuses on recent behavior, but can change the most.	0.05
Correlation (All Time) Calculated using the full available price history since Nov 14, 2024	0.05

Fundamentals

Market Cap MDCX : $6.07M GSK : $103.56B
EPS MDCX : -$1.92 GSK : £2.36
Total Revenue (TTM) MDCX : $0.00 GSK : £33.25B
Gross Profit (TTM) MDCX : $0.00 GSK : £24.35B
EBITDA (TTM) MDCX : -$36.18M GSK : £10.68B

Return for Risk

MDCX vs. GSK — Risk / Return Rank

Compare historical risk-adjusted metric ranks over the past 12 months.

MDCX

MDCX Risk / Return Rank: 8
MDCX Sharpe Ratio Rank: 13
MDCX Sortino Ratio Rank: 8
MDCX Omega Ratio Rank: 8
MDCX Calmar Ratio Rank: 3
MDCX Martin Ratio Rank: 7

GSK

GSK Risk / Return Rank: 84
GSK Sharpe Ratio Rank: 88
GSK Sortino Ratio Rank: 86
GSK Omega Ratio Rank: 83
GSK Calmar Ratio Rank: 83
GSK Martin Ratio Rank: 80

The rank (0–100) uses a weighted average of the Sharpe, Sortino, Omega, Calmar, and Martin percentile ranks for the trailing 12 months. Higher means stronger historical risk-adjusted performance within the peer group.

MDCX vs. GSK - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Medicus Pharma Ltd (MDCX) and GSK plc (GSK). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.

	MDCX	GSK	Difference
Sharpe ratio: Return per unit of total volatility	-0.70	1.68	-2.38
Sortino ratio: Return per unit of downside risk	-1.37	2.45	-3.82
Omega ratio: Gain probability vs. loss probability	0.83	1.29	-0.47
Calmar ratio: Return relative to maximum drawdown	-0.98	2.41	-3.39
Martin ratio: Return relative to average drawdown	-1.45	5.24	-6.68

MDCX vs. GSK - Sharpe Ratio Comparison

The current MDCX Sharpe Ratio is -0.70, which is lower than the GSK Sharpe Ratio of 1.68. The chart below compares the historical Sharpe Ratios of MDCX and GSK, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Drawdowns

MDCX vs. GSK - Drawdown Comparison

The maximum MDCX drawdown since its inception was -96.62%, which is greater than GSK's maximum drawdown of -55.70%. Use the drawdown chart below to compare losses from any high point for MDCX and GSK.

Drawdown Indicators

	MDCX	GSK	Difference
Max Drawdown Largest peak-to-trough decline	-96.62%	-55.70%	-40.92%
Max Drawdown (1Y) Largest decline over 1 year	-90.62%	-18.53%	-72.09%
Max Drawdown (3Y) Largest decline over 3 years	—	-28.46%	—
Max Drawdown (5Y) Largest decline over 5 years	—	-50.10%	—
Max Drawdown (10Y) Largest decline over 10 years	—	-50.10%	—
Current Drawdown Current decline from peak	-96.46%	-14.05%	-82.41%
Average Drawdown Average peak-to-trough decline	-60.11%	-18.85%	-41.26%
Ulcer Index Depth and duration of drawdowns from previous peaks	61.30%	8.49%	+52.81%

Volatility

MDCX vs. GSK - Volatility Comparison

Medicus Pharma Ltd (MDCX) has a higher volatility of 33.61% compared to GSK plc (GSK) at 8.74%. This indicates that MDCX's price experiences larger fluctuations and is considered to be riskier than GSK based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	MDCX	GSK	Difference
Volatility (1M) Calculated over the trailing 1-month period	33.61%	8.74%	+24.87%
Volatility (6M) Calculated over the trailing 6-month period	123.42%	19.87%	+103.55%
Volatility (1Y) Calculated over the trailing 1-year period	126.72%	26.94%	+99.78%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	130.72%	25.39%	+105.33%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	130.72%	22.97%	+107.75%

Dividends

MDCX vs. GSK - Dividend Comparison

MDCX has not paid dividends to shareholders, while GSK's dividend yield for the trailing twelve months is around 3.47%.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
GSK GSK plc	3.47%	3.42%	4.60%	3.75%	5.47%	4.99%	5.59%	4.35%	5.65%	5.83%	6.86%	5.93%
MDCX Medicus Pharma Ltd	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Financials

Frequently Asked Questions

Can I hold both MDCX and GSK in my portfolio?

MDCX and GSK have a correlation of 0.05, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, MDCX or GSK?

MDCX has higher volatility (33.61%) compared to GSK (8.74%). In terms of maximum drawdown, MDCX dropped -96.62% vs GSK's -55.70%.

Which has better risk-adjusted returns?

GSK currently has the higher Sharpe Ratio (1.68 vs -0.70), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.